HHS centralized federal agencies and private industry into pandemic countermeasure pipeline

Fourteen years prior to the COVID-19 pandemic, the Department of Health and Human Services (HHS) established the Public Health Emergency Medical Countermeasures Enterprise (PHEMCE). This initiative centralized the functions of seven federal agencies—including the CDC, FDA, NIH, DOD, DHS, and VA—into a government-directed countermeasure pipeline.

This structure, described as a ‘Pandemic-Industrial Complex,’ explicitly integrates private industry, including pharmaceutical manufacturers and biotechnology companies, into the federal framework. The system aims to streamline regulation, increase industry access to agencies, and provide liability protections while managing everything from threat detection and research to procurement and deployment.

Concerns have been raised regarding the national security implications of centralizing the institutions that define biological threats with those that fund research, regulate products, and manage stockpiles. This follows acknowledgments from various entities, including the FBI, CIA, and Germany’s Federal Intelligence Service (BND), that the COVID-19 pandemic was ‘likely’ the result of a laboratory incident involving engineered pathogens.